Azacitidine: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Azacitidine. Educational only — not medical advice.
Labeled uses
ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.
Source: FDA labeling via NIH DailyMed (set 0e95e33f…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.